Pegylated Interferon Alpha2A

Infection

M.D. Anderson Cancer CenterPhase 3Dormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Infection cohort.

Asset / Sponsor	Phase	Rating
SULFAMETHOXAZOLE Radboud University Medical Center	Phase 4	A
Trimethoprim Radboud University Medical Center	Phase 4	A
Ciprofloxacin Radboud University Medical Center	Phase 4	BBB
Aztreonam Liverpool Heart and Chest Hospital NHS Foundation Trust	Phase 4	BB
FILGRASTIM Cellerant Therapeutics	Phase 3	BB

View all 50 →

Same molecule, other indications

Pegylated Interferon Alpha2A is also rated in:

hepatitis C virus infectionDormant

A

Indicative ·

81 / 100

chronic hepatitis C virus infectionDormant

A

Indicative ·

81 / 100

chronic hepatitis B virus infectionDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.